BioCryst Non Current Assets Total from 2010 to 2025
| BCRX Stock | USD 7.22 0.03 0.41% |
Non Current Assets Total | First Reported 1994-03-31 | Previous Quarter 70.1 M | Current Value 58.7 M | Quarterly Volatility 18.9 M |
Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 979.9 K, Interest Expense of 103.4 M or Selling General Administrative of 265.1 M, as well as many indicators such as Price To Sales Ratio of 3.28, Dividend Yield of 0.0 or Days Sales Outstanding of 60.83. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.
BioCryst | Non Current Assets Total | Build AI portfolio with BioCryst Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.